Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483366 · ClinicalTrials.gov registry record · Phase 1
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00483366 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 13 participants.
The verdict
NCT00483366, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with gemcitabine and capecitabine may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine and capecitabine when given together with imatinib mesylate in treating patients with advanced solid tumors.
Interventions
- GENETIC mutation analysis
- DRUG imatinib mesylate
- DRUG capecitabine
- DRUG gemcitabine hydrochloride
- GENETIC nucleic acid sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-08-15 |
| Est. Completion | 2011-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00483366
The ClinicalTrials.gov registry entry for NCT00483366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mutation analysis is the first listed.
NCT00483366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00483366 about?
NCT00483366 is a clinical study titled "Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors". RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from div...
What is the current status of trial NCT00483366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2006-08-15. Estimated completion is 2011-03-29.
What interventions are being tested in trial NCT00483366?
The interventions under investigation include: mutation analysis (GENETIC), imatinib mesylate (DRUG), capecitabine (DRUG), gemcitabine hydrochloride (DRUG), nucleic acid sequencing (GENETIC).
Who is sponsoring clinical trial NCT00483366?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.